Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

CrownBio releases further data on MuScreen models
April 2018
SHARING OPTIONS:

SAN DIEGO—Crown Bioscience, the wholly owned subsidiary of Crown Bioscience International, shared new data the other month supporting the immunocompetent models of MuScreen, their large-scale immunotherapy screening platform. MuScreen interrogates a panel of common syngeneic tumor models to support the evaluation of immuno-oncology agents. CrownBio’s syngeneic models feature immunogenomic (sequencing) data, response to standard-of-care agents (including checkpoint inhibitor benchmarking) and immunophenotyping (FACS) analysis. The platform takes a selection of the models and incorporates shared vehicles in high-throughput format for quick, cost-effective results. The resulting data can be used to quantify model-specific efficacy, measure resistance, clarify pharmacodynamic effects and determine potential combination strategies.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.